Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 14/03/2024

    Next milestone in the treatment of liver tumors and acute and chronic liver diseases

    The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
  • Press release - 24/03/2021

    Liver cancer: which patients benefit from immunotherapy?

    Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
  • Organ failure due to fatty liver - 24/09/2020 Drawing of a human torso with a liver in red.

    HepaRegeniX develops an active substance for liver regeneration

    When the liver stops regenerating on its own, it might be possible in future for doctors to intervene with a chemical agent. Tübingen-based HepaRegeniX GmbH is developing a promising candidate with the aim of improving the treatment of both acute and chronic liver failure.

    https://www.gesundheitsindustrie-bw.de/en/article/news/heparegenix-develops-active-substance-liver-regeneration
  • Press release - 10/07/2024

    HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

    HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration
  • Press release - 18/01/2024

    Indicator for liver health status identified

    A high-fat, high-sugar diet damages the liver in the long term. Scientists at the German Cancer Research Center (DKFZ) have now identified a characteristic change in the molecular signaling pathways of liver cells in mice that were exposed to such a diet for weeks. It fuels the division activity of hepatocytes and correlates with the risk of patients suffering liver failure after liver surgery.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/indicator-liver-health-status-identified
  • Press release - 07/05/2024

    Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects

    Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
  • Press release - 30/08/2021

    CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-preclinical-data-demonstrates-significant-reduction-liver-fibrosis-mrna-therapeutic
  • Press release - 12/03/2025

    Hepatic stellate cells control liver function and regeneration

    Until now, doctors knew hepatic stellate cells mainly as drivers of liver fibrosis. The actual functions have hardly been studied to date. Researchers from the German Cancer Research Center, the Mannheim Medical Faculty and Columbia University have now published that hepatic stellate cells control liver metabolism as well as liver regeneration and size. The results of the study could contribute to new therapeutic approaches for liver diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hepatic-stellate-cells-control-liver-function-and-regeneration
  • Press release - 23/05/2023

    B cells promote liver cancer with dangerous dual strategy

    Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. In both mice and humans with NASH, they found increased numbers of activated B cells in the gastrointestinal tract.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/b-cells-promote-liver-cancer-dangerous-dual-strategy
  • Dossier - 09/03/2015 22868_de.jpg

    Advances in the study and treatment of liver diseases

    Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/advances-in-the-study-and-treatment-of-liver-diseases
  • Press release - 04/03/2025

    Clusters of Metabolic Dysfunction-Associated Steatotic Liver Disease for Precision Medicine

    People with metabolic dysfunction-associated steatotic liver disease (MASLD) and more so with metabolic dysfunction-associated steatohepatitis and MASLD-associated hepatic fibrosis can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular and chronic kidney disease, and cancers. Future research might be beneficial for implementing precision medicine in MASLD.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/clusters-metabolic-dysfunction-associated-steatotic-liver-disease-precision-medicine
  • Press release - 13/02/2025

    Guardian molecule keeps cells on track – new perspectives for the treatment of liver cancer

    A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great importance for cancer medicine because a change of identity of cells has come into focus as a fundamental principle of carcinogenesis for several years. The research team was able to show that the newly discovered guardian is so powerful that it can slow down highly potent cancer drivers and cause malignant liver tumors to regress in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-molecule-keeps-cells-track-new-perspectives-treatment-liver-cancer
  • Press release - 06/07/2021

    High-throughput metabolic profiling of single cells

    Scientists from the EMBL and the German Cancer Research Center have presented a new method for generating metabolic profiles of individual cells. The method, which combines fluorescence microscopy and a specific form of mass spectroscopy, can analyze over a hundred metabolites and lipids from more than a thousand individual cells per hour. Researchers expect the method to better answer a variety of biomedical questions in the future.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-throughput-metabolic-profiling-single-cells
  • Overview

    Red biotechnology

    https://www.gesundheitsindustrie-bw.de/en/article/biotech
  • Dossier - 01/10/2012 virtual molecular structure

    Systems biology understanding complex biological systems

    Systems biology studies complex interactions within biological systems on the genome proteome and organelle level. Many techniques from the fields of systems theory and associated fields can be used to gain an understanding of the behaviour and biological mechanisms of cellular systems.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/systems-biology-understanding-complex-biological-systems
  • Press release - 20/01/2025

    New approach to fighting cancer: energy trap for tumor cells

    Glycolysis is an important sugar degradation pathway that cancer cells in particular depend on. Scientists at the German Cancer Research Center (DKFZ) have now shown that liver cancer cells in mice and humans depend on a key enzyme of glycolysis, Aldolase A. When it is switched off, glycolysis reverses from an energy-producing to an energy-consuming process.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-fighting-cancer-energy-trap-tumor-cells
  • Press release - 16/09/2021

    Organ twin: a “flight simulator” for surgeons

    Cyber Valley researchers have created medical educational tools that could potentially train the surgeons of the future, much like flight simulators train pilots. The team developed a range of artificial organ phantoms to serve as training platforms for surgeons. Thanks to the structured data of experienced medical professionals, a quantitative and objective assessment of a trainee’s skills can be assessed in real time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/organ-twin-flight-simulator-surgeons
  • Dossier - 10/03/2014 20939_de.jpg

    Cancer therapy and cancer diagnostics

    Thanks to improved diagnostics and therapy, today’s cancer patients can live considerably longer than patients several years ago. Nevertheless, some cancers, especially the strongly metastatic ones, are difficult to treat. Therapies targeting immune cells or cancer stem cells could potentially improve the current situation.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-therapy-and-cancer-diagnostics
  • Press release - 04/10/2023

    Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion

    A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion
  • Press release - 13/06/2024

    Which of the two DNA strands is damaged influences the cell's mutation profile

    Cancer genomes are the result of diverse mutation processes. Scientists have analyzed the molecular evolution of tumors after exposure to mutagenic chemicals. DNA lesions that persists unrepaired over several cell generations lead to sequence variations at the site of damage. This enabled the researchers to distinguish the contribution of the triggering lesion from that of the subsequent repair in shaping the mutation pattern.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/which-two-dna-strands-damaged-influences-cells-mutation-profile
  • Press release - 30/10/2024

    Diabetes switch in DNA: Non-coding region in the genome influences ONECUT1 gene

    They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role in the development of this disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-switch-dna-non-coding-region-genome-influences-onecut1-gene
  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Press release - 20/06/2023

    Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future

    KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuberculosis-therapy-smallest-particles-will-deliver-drug-lungs-future
  • Press release - 15/11/2023

    Nanoparticles for optimized cancer therapy

    Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanopartikel-fuer-optimierte-krebstherapie
  • Dossier - 05/11/2012 18550_de.jpg

    Cancer basic research successes and trends

    Science is approaching cancer treatment by using new systems biology approaches and setting up large-scale multidisciplinary projects such as the International Cancer Genome Consortium. Progress in genome, epigenome and gene expression analyses of cancer cells, new insights into the regulation and interaction of cells gained in cooperation with stem cell research and virus research contributes to gaining a causal understanding of cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/cancer-basic-research-successes-and-trends

Page 1 / 2

sb_search.block.search_result.other.pages

  • 1
  • 2
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search